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Abstract
Aim: Assess the ability of a panel of gingival crevicular fluid (GCF) biomarkers
as predictors of periodontal disease progression (PDP).
Materials and methods: In this study, 100 individuals participated in a 12-month
longitudinal investigation and were categorized into four groups according to
their periodontal status. GCF, clinical parameters and saliva were collected bi-
monthly. Subgingival plaque and serum were collected bi-annually. For 6 months,
no periodontal treatment was provided. At 6 months, patients received periodon-
tal therapy and continued participation from 6 to 12 months. GCF samples were
analysed by ELISA for MMP-8, MMP-9, Osteoprotegerin, C-reactive Protein
and IL-1b. Differences in median levels of GCF biomarkers were compared
between stable and progressing participants using Wilcoxon Rank Sum test
(p = 0.05). Clustering algorithm was used to evaluate the ability of oral biomar-
kers to classify patients as either stable or progressing.
Results: Eighty-three individuals completed the 6-month monitoring phase. With
the exception of GCF C-reactive protein, all biomarkers were significantly higher
in the PDP group compared to stable patients. Clustering analysis showed highest
sensitivity levels when biofilm pathogens and GCF biomarkers were combined
with clinical measures, 74% (95% CI = 61, 86).
Conclusions: Signature of GCF fluid-derived biomarkers combined with patho-
gens and clinical measures provides a sensitive measure for discrimination of PDP
(ClinicalTrials.gov NCT00277745).
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Despite advances in research method-
ology and laboratory assays in order
to identify factors associated with
chronic periodontal disease, it is still
unclear how to potentially predict
periodontal disease progression
(PDP). Periodontitis has been clini-
cally characterized as episodes of
acute exacerbations of destruction
followed by periods of quiescence and
stability (Goodson et al. 1982, 1984,
Socransky et al. 1984). The elusive
nature of the disease is further com-
plicated by the fact that different
teeth within the same patient, as well
as different sites around the same
tooth can display varying degrees of
disease severity, all undergoing PDP.
Clinical measures of periodontitis
such as pocket depth (PD), clinical
attachment level (CAL) or bleeding
on probing (BOP) have limitations to
provide the clinician with real-time
evaluation of disease status. Further-
more, these clinical measures are poor
predictors of future PDP (Lindhe
et al. 1983). An ideal diagnostic tool
would not only detect the presence
and severity of the disease but also
predict subsequent clinical course of
the infection (McCulloch 1994).
Extensive research has been done
in the area of the host response bio-
chemical markers of periodontal dis-
ease. It is unlikely that a stand-alone
biomarker will be able to fulfil the
criteria of predicting future disease
destruction. A cross-sectional study
demonstrated that the combination
of saliva-based biomarkers and peri-
odontal biofilm pathogens suggest
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potential diagnostic value for identi-
fying periodontal disease status
(Ramseier et al. 2009). Later, a lon-
gitudinal investigation of the same
patient population demonstrated the
ability of saliva-derived biomarkers
and periodontal pathogens to predict
PDP (Kinney et al. 2011).
Gingival crevicular fluid (GCF) is
a serum exudate found in the gingival
sulcus (McCulloch 1994). As the fluid
traverses from the microcirculation
across inflamed periodontal tissues, it
carries biological molecular markers
gathered from the surrounding site.
GCF is an attractive oral fluid due to
its ease of collection and ability for
the clinician to sample multiple sites
within the oral cavity simultaneously.
In a molecular epidemiologic study,
Offenbacher et al. described new clin-
ical categories represented by distinct
biological phenotypes based on clini-
cal, microbial, inflammatory and
host-response measures for periodon-
tal disease identification. Interest-
ingly, the authors identified that
individuals with deep pocket depths
and more severe BOP had elevated
levels of GCF Interleukin-1b (IL-1b)
and Interleukin-6 (IL-6) (Offenbacher
et al. 2007).
To date, limited research has
been completed in the usage of GCF
as a diagnostic measure of periodon-
tal disease. The aim of this follow-up
study was to test the utility of GCF
biomarkers as a potential predictor
of periodontal disease progression.
Material and methods
Patient population
One hundred periodontally healthy
and diseased individuals were
recruited at the Michigan Center for
Oral Health Research clinic between
2005 and 2007 (University of Michi-
gan, Ann Arbor, Michigan). The
study was approved by the University
of Michigan Health Sciences Institu-
tional Review Board and registered
with the NIH clinical registry (Clini-
calTrials.gov NCT00277745). Clinical
and demographic baseline character-
istics of this cohort have been previ-
ously published and are described in
Table S1 (Ramseier et al. 2009, Kin-
ney et al. 2011). Individuals age
18 years and older were eligible for
the study. All individuals possessed
≥20 teeth, had not received periodon-
tal treatment or antibiotic therapy
for medical or dental reasons for
3 months prior to the start of the
investigation, and were not taking
long-term medications affecting peri-
odontal status. Study exclusionary
factors included a history of meta-
bolic bone diseases, autoimmune
diseases, unstable diabetes or post-
menopausal osteoporosis. Pregnant
or lactating women were not allowed
to participate in the study.
Clinical measures
All teeth except third molars were
assessed for periodontal clinical mea-
sures by one of three calibrated exam-
iners (CR, JK and TM). Clinical
parameters, including PD, CAL and
BOP, were measured at six sites per
tooth. Other clinical assessments
included dichotomous measures of
plaque accumulation (PI) and gingi-
val redness index, as previously
described by Haffajee et al. (1983).
Based on clinical assessments,
patients were enrolled into a healthy/
gingivitis or periodontitis group.
Patients in the healthy and gingivitis
group exhibited <3 mm of CAL, no
PD >4 mm, and no radiographic
alveolar bone loss. Patients in the
periodontitis group exhibited a mini-
mum of four sites with evidence of
radiographic bone loss, at least four
sites with PD > 4 mm, and a mini-
mum of four sites with CAL > 3 mm.
Both groups were further classified
into subgroups based on additional
clinical criteria. Patients with
BOP ≤ 20% were categorized as
Healthy (H) (n = 18), and those with
BOP > 20% were categorized as Gin-
givitis (G) (n = 32). Within the peri-
odontitis group, those patients with
≤30% of sites with CAL > 3 mm
were classified as having Mild
Chronic Periodontitis (MP) (n = 28),
and those with >30% of sites with
CAL > 3 mm were categorized as
having Moderate-Severe Periodontitis
(SP) (n = 22) (Armitage 1999, Tonetti
& Claffey 2005). Standardized peri-
apical digital radiographs (Schick
Technologies, Long Island City, NY,
USA) were taken in the posterior den-
tition of all participants by a parallel
technique for the determination of
alveolar bone height at baseline, 6
and 12 months. Radiographic bone
loss was analysed by one calibrated
examiner equipped with a computer
software measurement tool (Emago,
Oral Diagnostic Systems, Amster-
dam, the Netherlands).
Figure 1 illustrates the timeline of
the study. There were two phases of
the investigation, disease-monitoring
phase (baseline to 6 months) and dis-
ease-recovery phase (6–12 months).
Patients were seen bi-monthly during
the study. In order to assess for PDP,
no periodontal therapy was provided
during the disease-monitoring phase.
At 6 months, all patients received
periodontal treatment. Those in the
healthy and gingivitis groups received
prophylaxis and oral hygiene instruc-
tion (OHI) and those in the periodon-
titis groups underwent scaling and
root planing (Sc/RP) and OHI.
Patients in the healthy and gingivitis
groups received a second prophylaxis
at 12 months, while those patients in
the periodontitis groups received peri-
odontal maintenance at each of the
remaining study visits. Tobacco ces-
sation counselling was not provided
to patients during the study. Any site
undergoing clinical attachment loss of
>2 mm from the baseline measure-
ment was deemed as “progressing”
and received rescue therapy consist-
ing of localized Sc/RP and local anti-
biotic delivery (Arestin, OraPharma,
Warminster, PA, USA), which has
demonstrated to improve periodontal
healing compared to Sc/RP alone
(Williams et al. 2001).
Fig. 1. Timeline of the study illustrating data collection and treatment delivery time
points during disease monitoring and recovery phases.
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Gingival crevicular fluid collection and
analysis
GCF was taken from the mesiobuc-
cal aspect of each site (tooth) for up
to 28 teeth per patient. Prior to the
collection, supragingival plaque was
removed using a sterile instrument.
The site was isolated using cotton
rolls and dried using a short blast of
air directly through the contact (not
into the sulcus/pocket). A methylcel-
lulose strip (Pro Flow, Inc., Amity-
ville, NY, USA) was inserted into
the sulcus/pocket until light resis-
tance was felt. The strip stayed in
position for 30 s. GCF volume was
immediately determined using a cali-
brated Periotron 6000 (Harco Elec-
tronics, Tustin, CA, USA). Strips
contaminated with blood or exceed-
ing the Periotron maximum detec-
tion limit were discarded and the site
was re-sampled after 90 s. GCF
strips were stored in cryovials at
80°C until extraction.
Eight sites were selected from
each participant using an algorithm
based on the patient’s baseline site
measures of CAL, PD, BOP and
group classification. Specifically, in
patients without periodontitis, sites
with PD less than 4 mm and/or
CAL less than 3 mm were ranked
higher, while in patients with peri-
odontitis, sites with PD greater than
4 mm and/or CAL greater than
3 mm were ranked higher. In
patients with gingivitis and periodon-
titis, sites were ranked even higher if
they had BOP. The eight highest-
ranked sites from each patient were
then selected and their samples were
pooled to create a subject-level GCF
sample. Each strip was washed five
times with 11 ll extraction solution
containing a proteinase inhibitor
combination of 1% aprotinin and
0.5% phenylmethylsulfonyl fluoride.
The total solution volume per strip
was 55 ll. Individual strips were cen-
trifuged at 2000 rpm at 4o C for
5 min. then pooled to give a total
solution volume per patient of 440 ll
(8 9 55 ll).
The GCF samples were quant-
itively analysed for the concentration
of C-reactive Protein (CRP), Osteo-
protegerin (OPG), Collagenase-2
(MMP-8), Gelatinase B (MMP-9),
and IL-1b using a Quantibody
Human Cytokine Array (RayBio-
tech, Inc., Norcross, GA, USA).
Whole saliva, serum and microbial plaque
biofilm
In order to elucidate the potential
value of oral-fluid biomarkers for
PDP, a clustering algorithm
described in the Statistical Methods
section was used. This analysis eval-
uated the results from GCF biomar-
kers from this study combined with
the results of salivary, serum and
pathogens biomarkers previously
published (Kinney et al. 2011).
Unstimulated whole saliva was
collected at the beginning of each
study visit with passive drooling into
sterile plastic tubes from all patients
(Mandel & Wotman 1976). Samples
were further placed on ice, aliquoted,
and supplemented with a proteinase
inhibitor combination of 1% aproti-
nin and 0.5% phenylmethylsulfonyl
fluoride prior to storage at 80°C.
Whole saliva samples were tested
for the presence of MMP-8 and -9,
Calprotectin, OPG, IL-1b, IL-2, IL-
4, IL-5, IL-6, IL-10, IL-13, tumour
necrosis factor-a (TNF), and inter-
feron-c and pyridinoline cross-links
of type I collagen (ICTP).
Twenty millilitres of whole blood
was collected at baseline, 6 months,
and 12 months. Once collected, sam-
ples were allowed to clot at room
temperature for 30 min. then centri-
fuged for 15 min. at 2600 rpm.
Approximately, one millilitre of
serum was aliquoted into individual
cryovials and stored at 80°C until
analysis. Serum samples were tested
for the presence of CRP, IL-1b, IL-
6, TNF-a, Calprotectin, OPG, ICTP,
MMP- 8 and -9.
Subgingival plaque biofilm was
collected from the mesiobuccal
aspect of all teeth at baseline, 6 and
12 months according to Shelburne
et al. 2008 (Shelburne et al. 2008).
The detection of Porphyromonas gin-
givalis, Prevotella intermedia, Tanne-
rella forsythia, Fusobacterium
nucleatum, Treponema denticola and
Campylobacter rectus were quanti-
tated by real-time quantitative PCR
(qPCR) as described by Mullally
et al. (Mullally et al. 2000).
Statistical methods
The level of analysis in this data is
the individual patient and all bio-
markers were log-transformed prior
to analysis to promote normality.
Mean longitudinal levels of each
GCF biomarker for each of the four
patient groups was computed at
baseline and each post-baseline time
point. Statistical significance of
changes from baseline was assessed
using the empirical (“robust”) stan-
dard error from Generalized Esti-
mating Equations to reflect the serial
correlation inherent in longitudinal
data. Given that there were 24 com-
parisons for each biomarker (six
post-baseline measures for each of
four patient groups), statistical sig-
nificance was defined as a p-value
less than 0.002 to maintain an over-
all false-positive rate of 0.05. Median
baseline biomarker levels (non-log-
transformed) were computed sepa-
rately for periodontally stable and
progressing patients, and differences
between the two groups were analy-
sed using a Wilcoxon Rank Sum test
with statistical significance defined as
a p-value less than 0.05. We used
hierarchical clustering (HC) to divide
patients into two groups based solely
upon their GCF biomarker levels.
HC considers GCF biomarker levels
and divides them into two groups
such that the two groups have the
smallest variability among all possi-
ble divisions into two groups, that
is, the GCF values within each clus-
ter are closer together than GCF
values from different clusters. HC
can be specified to generate more
than two clusters, but we chose two
clusters for ease of interpretation, as
these clusters were then compared to
the actual clusters of stable and pro-
gressing patients. HC was then
repeated separately for the plaque
pathogen levels, salivary biomarker
levels, serum biomarker levels and
clinical measures reported (Kinney
et al. 2011). An ideal clustering
result from HC would be one in
which all stable patients were in one
cluster and all progressing patients
were in the other cluster. Thus, the
ability of the HC-generated clusters
to discriminate between stable and
progressing patients was summarized
with sensitivity, specificity, positive
predictive value (PPV) and negative
predictive value (NPV). All calcula-
tions were done with the statistical
package R (R Foundation for Statis-
tical Computing, Vienna, Austria);
HC was implemented with the
library hclus.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Results
Recruitment/enrollment efforts for
the study were previously published
(Kinney et al. 2011). In total, 148
individuals were screened. Forty-
eight failed the clinical screening,
leaving 100 participants who were
stratified into four groups according
to their clinical criteria. One partici-
pant from the Moderate-Severe
group withdrew at the baseline visit,
leaving a total of ninety-nine partici-
pants. During disease progression
analysis, 83 participants completed
the study (15 H, 24 G, 24 MP and
20 SP), with 44 exhibiting PDP dur-
ing the disease-monitoring period (2
H, 5 G, 21 MP and 16 SP), while
39 demonstrated stability (13 H,
19 G, 3 MP, 4 SP). Results of sali-
vary and pathogen biomarkers asso-
ciated with periodontal disease
progression from this study were
previously published (Kinney et al.
2011). In general, the orders of mag-
nitude of GCF and saliva biomarker
levels were comparable to other
published reports for mediators such
as MMP-8, MMP-9, IL-1 beta and
OPG (Miller et al. 2006, Teles et al.
2009, 2010, Gursoy et al. 2010, Mir-
rielees et al. 2010, Salvi et al. 2010,
Sexton et al. 2011).
Longitudinal plots
The longitudinal plots of mean
(SD) of GCF biomarker levels
found among the four groups over
12 months are shown in Fig. 2. All
four patient groups had significant
reductions of GCF MMP-8 at
month 2 compared to baseline
(p < 0.002). Continued significant
reduced levels were seen in the
healthy and gingivitis groups at
month 4 with only the gingivitis
group having sustained significant
lower levels of GCF MMP-8 levels
at month 6 compared to baseline
(p < 0.002). During disease recovery
phase both mild and moderate/
severe disease groups demonstrated
significant lower levels of GCF
MMP-8 (p = 0.001). Healthy and
gingivitis groups showed significant
lower GCF MMP-8 levels compared
to baseline levels only at month 10.
Regarding GCF MMP-9 levels, sig-
nificantly increased expressions were
seen in all patient groups at month 6
compared to baseline (p = 0.001). In
addition, healthy and gingivitis
groups had higher levels of GCF
MMP-9 at months 8 and 12 com-
pared to baseline (p < 0.002). Gingi-
vitis group demonstrated significant
decreases in GCF CRP levels at
month 4, 8 and 10 compared to base-
line (p = 0.001). Significant decreases
in GCF CRP concentrations were
also observed for both periodontitis
groups at month 8 with only the mod-
erate/severe periodontitis group
showing significantly reduced levels
at month 10 compared to baseline
(p =0.002). Regarding GCF OPG lev-
els, healthy and gingivitis groups had
significantly higher GCF OPG levels
at month 6 compared to baseline
(p < 0.002) with no further significant
findings. Both mild and moderate/
severe periodontitis groups showed
significant decreased concentrations
of GCF IL-1b at months 10 and 12,
respectively, when compared to base-
line (p < 0.001).
Baseline results comparing individual
GCF biomarkers
Median levels of each GCF biomar-
ker for stable and progressing
patients are shown in Table 1.
Fig. 2. Panels displaying mean longitudinal levels with standard error bars of each
GCF biomarker for each patient group. Statistically significant changes from baseline
to post-baseline time point of biomarker concentrations within each patient group are
depicted by *p < 0.002.
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Biomarkers were ordered from least
to largest p-value, giving a ranking
of the relative significance of the bio-
markers.
All of the biomarkers except CRP
showed significant differences in the
median levels of the stable and pro-
gressing patients. IL-1b had the most
significant difference (p < 0.001),
indicating statistically significant
higher levels of GCF IL-1b in the
patients who had disease progression
compared to those participants who
did not display disease progression.
The second GCF biomarker that
demonstrated significance between
the stable and progressing patient
group medians was OPG with a
p-value of 0.003. A p-value of 0.006
was seen in the levels of GCF MMP-
8 between stable patients and PDP
patients. MMP-9 median levels
between the stable and progressing
patients also reached significance at
a p-value of 0.03. CRP was not sig-
nificantly different between the two
groups. When considering the rank-
ing order of these biomarkers, IL-1b
was the strongest, followed by OPG,
MMP-8 then MMP-9.
Sensitivity/specificity and PPV/NPV
A clustering algorithm, as described
in the Statistical Methods section,
was used to evaluate the ability of
biomarkers in saliva, plaque, serum,
GCF or clinical measures, alone or
in groups. The algorithm correctly
classified patients as either stable or
progressing based upon the sensitiv-
ity, or proportion of correctly classi-
fied progressing patients, and
specificity, or proportion of correctly
classified stable patients (Table 2). In
general, the greatest sensitivity
tended to be with saliva biomarkers
and greatest specificity with GCF
biomarkers (Table 2). However,
varying levels of sensitivity and spec-
ificity in lower ranges (<60%) were
noted for many permutations of the
different parameters evaluated. Pla-
que pathogens provided good sensi-
tivity and specificity for prediction
of PDP, 63% (95% CI = 49, 77) and
69% (95% CI = 55, 83) respectively.
A high sensitivity was seen when
using only salivary biomarkers, 93%
(95% CI = 83, 98), but this individ-
ual cluster of biomarkers had very
low specificity results, 26% (95%
CI = 15, 42). Sensitivity levels
increased to 72% (95% CI = 58, 84)
when plaque pathogens were paired
with GCF biomarkers. This pairing
of clusters resulted in a slight lower-
ing of specificity, 67% (95%
CI = 52, 81). Further increases in
sensitivity were reached when peri-
odontal measures were clustered
with plaque pathogens and GCF
biomarkers, 74% (95% CI = 61, 86).
When these three parameters are
clustered, the specificity rises slightly
to 68% (95% CI = 54, 82). When
salivary biomarkers were clustered
with periodontal measures, plaque
pathogens and GCF, sensitivity lev-
els reduced to 70% (95% CI= 56,
83), but specificity levels increased to
the highest, 71% (95% C = 56, 84).
Table S2 represents both positive
and negative predict value (PPV/
NPV) of biomarkers in saliva, pla-
que, serum, GCF or clinical mea-
sures, alone or in groups, associated
with periodontal disease progression.
Plaque pathogens paired with GCF
biomarkers demonstrated a 70%
(95% CI =57, 83) PPV and 68%
(95% CI = 54, 82) NPV respectively.
Further increases in PPV were
reached when periodontal measures
were clustered with plaque patho-
gens, salivary and GCF biomarkers,
73% (95% CI = 59, 86). The maxi-
mum NPV of 70% (95% CI = 55,
84) was reached when periodontal
measures were clustered together
with plaque pathogens and GCF bi-
omarkers.
Discussion
In this study we sought to examine
the ability of a cluster of GCF bio-
markers alone or in combination
with saliva, plaque pathogens, and/
or clinical measures to evaluate a
patient’s risk of active periodontal
disease. Singular analysis of GCF
biomarkers offer utility in prediction
of PDP; however, greater predict-
ability of PDP is noted when GCF
biomarkers are combined with other
clinical and biological measures.
A previous study using the same
patient population found that anaer-
obic pathogens P. gingivalis (Pg) and
T. denticola (Td) in combination
with MMP-8 and OPG have the
capacity to predict a patient’s peri-
odontal status (Ramseier et al.
2009). This cohort of patients was
then longitudinally followed during
a disease-monitoring, non-treatment
phase. We then identified clusters of
host-response salivary biomarkers
and periodontal pathogens that
appear to be indicators of periodon-
tal break down (Kinney et al. 2011).
In this investigation we now include
in the model the findings of the
GCF biomarkers for a more com-
prehensive outcome of using oral flu-
ids and plaque pathogens for disease
prediction. To our knowledge, this is
the first time such a comprehensive
analysis on disease progression has
been presented.
Periodontal disease is a multi-
factorial infection; therefore, when
seeking prognostic biomarkers to
provide the highest levels of sensitiv-
ity and specificity for disease pro-
gression, one must look beyond an
individual biomarker and consider
combinations of valuable host-
responses. When we ranked our find-
ings in terms of levels of sensitivity
and specificity and PPV/NPV, we
found that using only periodontal
pathogens as predictors of disease
provided us with good sensitivity
and specificity results. Our results
found that Pg, Tf and Td in
conjunction with E.corrodens (Er),
F. nucleatun (Fn) and P. intermedia
(Pi), equally contributed to well over
50% sensitivity and specificity
values, 63% and 69% respectively.
Several other investigators have
reported the prognostic ability of
Pg, A. actinomycetemcomitans (Aa),
T. forsythia (Tf), Td (Haffajee et al.
Table 1. Differences in individual GCF biomarkers at baseline between stable and pro-
gressing patients.
Biomarker Stable patients Progressing patients p-value for
difference
IL1-beta 118 (92–998) 482 (15–908) <0.001
OPG 29 (0–2,640) 172 (0–1,649) 0.003
MMP-8 9,328 (4,695–26, 697) 10, 931 (4,610–23, 772) 0.006
MMP-9 8,378 (2,239–29, 409) 9,323 (3,464–25, 220) 0.03
CRP 1,929 (32–18, 862) 1,624 (8–19, 459) 0.94
Median (range, pg/ml).
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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1991, Machtei et al. 1997, 1999,
Timmerman et al. 2000, Tran et al.
2001, Byrne et al. 2009). It should
be noted, however, that other studies
have not supported the same find-
ings (Wennstrom et al. 1987, Mac-
farlane et al. 1988, Listgarten et al.
1991, Silva et al. 2008). Interestingly,
GCF biomarkers alone provided us
with low sensitivity and high speci-
ficity values, 23% and 95% respec-
tively. Although GCF biomarkers,
especially IL-1b, demonstrated a sig-
nificant difference at baseline
between progressing and stable
patients, when analysed alone they
did not demonstrate to be a strong
predictor of periodontal disease pro-
gression.
Our results show improvements
in sensitivity and specificity when
periodontal pathogens are combined
with GCF biomarkers. Silva et al.
examined periodontopathic bacteria
and GCF biomarkers and found
higher levels of Pg, Aa, Tf and
RANK-L, IL-1b, and MMP-13 in
patients with active sites. In that
study periodontal progression was
determined using the tolerance
method. Their results found that ele-
vated levels of RANK-L, IL-1b and
MMP-13 along with increases in Pg
and Aa were indicative of periodon-
tal lesions undergoing attachment
loss (Silva et al. 2008).
It appears from our data that the
highest level of specificity was reached
when combining clusters of salivary
and GCF biomarkers with pathogens
and clinical measures. In a recent
study by Nomura et al. (2012),
chronic periodontitis patients were
seen longitudinally for 18 months
while disease progression was mea-
sured. Salivary samples were collected
and evaluated for counts of Pg, Pi
and Tf and intracellular enzyme levels
of aspartate aminotransferase, ala-
nine aminotransferase (ALT), lactate
dehydrogenase, alkaline phosphatase
and free haemoglobin biomarkers. In
their study, periodontal disease pro-
gression was set as at least one site
with >3 mm loss of attachment com-
pared with baseline. Findings
showed that Pg and Pi were both
significant predictors of disease pro-
gression. However, higher levels of
sensitivity and specificity were
reached when Pg was combined with
salivary ALT.
The use of GCF suggests poten-
tial diagnostic value to identify peri-
odontal disease activity and response
to therapy. Our results demonstrated
that GCF biomarkers itself had
good PPV 83% (95% CI = 59, 97)
but low NPV 52% (95% CI = 41,
64). The highest PPV and NPV
results were reached when GCF bio-
markers were combined with plaque
pathogens and clinical measures
73% (95% CI = 59, 85) and 70%
(95% CI = 55, 84), respectively. The
addition of a fourth component, sali-
vary biomarkers, made only slight
changes to the PPV 73% (95%
CI = 59, 86) and NPV 68% (95%
CI = 52, 81) results. Recently, a
comprehensive proteomic analysis of
Table 2. Changes in true positive and negative rates using individual versus clusters of oral fluid biomarkers, plaque pathogens and clinical
measures derived at baseline.
Number of Items
in Cluster
Salivary
Biomarkers
Plaque
Pathogens
Serum
Biomarkers
Periodontal
Measures
GCF
Biomarkers
Sensitivity Specificity
Estimate (%) 95% CI Estimate (%) 95% CI
1 ■ 93 (83, 98) 26 (15, 42)
■ 63 (49, 77) 69 (55, 83)
■ 45 (32, 61) 61 (46, 76
■ 30 (18, 45) 97 (88, 100)
■ 23 (13, 38) 95 (85, 99)
2 ■ ■ 58 (44, 73) 72 (57, 85)
■ ■ 47 (33, 62) 45 (31, 62)
■ ■ 35 (23, 51) 71 (56, 84)
■ ■ 28 (17, 44) 69 (55, 83)
■ ■ 47 (33, 62) 61 (46, 76)
■ ■ 67 (53, 81) 68 (54, 82)
■ ■ 72 (58, 84) 67 (52, 81)
■ ■ 59 (45, 74) 59 (44, 75)
■ ■ 57 (43, 72) 55 (40, 71)
■ ■ 43 (30, 59) 95 (84, 99)
3 ■ ■ ■ 47 (33, 62) 45 (31, 62)
■ ■ ■ 63 (49, 77) 71 (56, 84)
■ ■ ■ 44 (31, 60) 74 (60, 87)
■ ■ ■ 58 (44, 73) 43 (29, 61)
■ ■ ■ 58 (44, 73) 39 (26, 57)
■ ■ ■ 47 (33, 62) 68 (54, 82)
■ ■ ■ 67 (53, 81) 68 (53, 82)
■ ■ ■ 81 (69, 91) 39 (26, 57)
■ ■ ■ 74 (61, 86) 68 (54, 82)
■ ■ ■ 66 (52, 79) 57 (42, 73)
4 ■ ■ ■ ■ 63 (49, 77) 70 (55, 84)
■ ■ ■ ■ 58 (44, 73) 39 (26, 57)
■ ■ ■ ■ 70 (56, 83) 71 (56, 84)
■ ■ ■ ■ 65 (51, 79) 41 (27, 58)
■ ■ ■ ■ 81 (69, 91) 41 (27, 58)
5 ■ ■ ■ ■ ■ 70 (56, 83) 70 (55, 84)
GCF, gingival crevicular fluid; CI, confidence interval; ■, included in clustering algorithm.
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GCF from a periodontally healthy
and disease population was per-
formed using liquid chromatography
and tandem mass spectrometry,
which demonstrated that the bacte-
rial proteins identified in both data
sets differed, and no crossover of
proteins was observed (Baliban et al.
2012). These results elucidate the
potential for human and bacterial
biomarkers present within GCF as
potential markers of periodontal dis-
ease activity. Similarly, Tsuchida
et al. described a different methodol-
ogy for extracting the GCF proteins
and found a significantly higher con-
centration of superoxide dismutase
1, apolipoprotein A-I, and dermici-
din to be highly expressed within
samples from chronic periodontitis
individuals (Tsuchida et al. 2012).
Gingival crevicular fluid has also
demonstrated a potential value to
evaluate periodontal therapy effi-
cacy. Our results showed significant
reduction of GCF cytokines after
periodontal therapy. It is in accor-
dance with recent results by Oliveira
et al., who investigated changes in
levels of GCF cytokines after peri-
odontal therapy and found signifi-
cant reduction in GCF IL-1b, GM-
CSF and the ratio IL-1b/IL-10 (De
Lima Oliveira et al. 2012).
Although we included serum bio-
markers into the overall analysis in
our study, we found that serum did
not play an important diagnostic
role in identifying patients who were
susceptible to future periodontal
progression (Kinney et al. 2011).
Similarly, Takahashi et al. found no
significance on serum IL-6 levels on
periodontitis patients, although
increased expression was found in
the gingival tissues (Takahashi et al.
1994). In a recent study, Becerik
et al. investigated GCF and plasma
acute-phase cytokines levels in differ-
ent periodontal diseases and demon-
strated that plasma cytokine levels
are not related to the inflammatory
changes occurring in the disease peri-
odontal tissues (Becerik et al. 2012).
Our findings suggest that of the
categories of saliva, serum, GCF,
clinical measures, and pathogen bio-
markers identified, the greatest
degree of sensitivity was noted with
saliva biomarkers and greatest speci-
ficity was with GCF biomarkers on
the identification of periodontal dis-
ease progression. The overall bal-
ance of sensitivity and specificity
was most consistent when the five
parameters were examined in combi-
nation. Clinical implications include
improved patient monitoring and
control of disease activity. Thus, the
identification of patients with multi-
ples sites demonstrating high suscep-
tibility for disease activity would
assist the establishment of a person-
alized approach helping to identify
or targeting patient-specific risk
factors.
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Clinical Relevance
Scientific rationale for the study:
Current periodontal diagnostic
methods are limited in their ability
to provide the clinician with real-
time evaluation of disease status.
The aim of this study was to assess
the ability of a panel of gingival crevi-
cular fluid biomakers as predictors of
periodontal disease progression.
Principal findings: Reliable levels of
predictability of periodontal disease
progression were seen when GCF
biomarkers were combined with
other clinical and biological mea-
sures of disease activity.
Practical implications: Utilization
of host oral fluid biomarkers as pre-
dictors of periodontal disease pro-
gression may offer improved patient
monitoring and disease control.
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